# Akeso, Inc. (AKESF)

> Source: Nexqual · https://nexqual.com/AKESF · data as of 2026-10-22 20:00 UTC · cite as "Nexqual, Akeso, Inc. (AKESF), nexqual.com/AKESF" · informational, not investment advice.

**Price:** USD 10.84 (-10.68% on the day) · last close of Oct 22, 2026; US market closed, not a live price. Prev close 12.14 · day 10.65–11.1 · 52w 10.5–19.49 · market cap $9.99B · PNK

## Key facts
- Analysts: None.
- Total return with dividends: 1Y -27.9% vs S&P 500 +14.4%; 5Y +116.8% vs S&P 500 +77.0%.
- Next earnings: 2026-08-27, EPS estimate USD —, revenue estimate $0K.

## Analysts
Consensus None.

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2023-05-15) |
|---|---|---|
| Total return | -27.9% | +116.8% |
| S&P 500 (SPY) | +14.4% | +77.0% |
| Per year | -28.0% | +25.2% |
| Volatility (annualized) | 61.1% | 56.0% |
| Max drawdown | -45.6% (Apr 2026→Jun 2026) | -54.2% (Aug 2025→Jun 2026) |

## Peers (Biotechnology)
PCVX (Vaxcyte, Inc.) USD 61.51 -2.14% · KRYS (Krystal Biotech, Inc.) USD 314.39 -1.79% · MDGL (Madrigal Pharmaceuticals, Inc.) USD 440.52 -2.83% · KYMR (Kymera Therapeutics, Inc.) USD 110.69 -0.14% · PTGX (Protagonist Therapeutics, Inc.) USD 138.69 -0.60% · TWST (Twist Bioscience Corporation) USD 137.94 +1.82%

## More
Full page: https://nexqual.com/AKESF · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter | — | — | — | $0 | — |
| Next quarter | — | — | — | $0 | — |
| Current fiscal year (ends 2026-12-31) | — | — | — | $4.62B | — |
| Next fiscal year (ends 2027-12-31) | — | — | — | $6.99B | — |